

Claims

This listing of claims will replace all prior listings of claims:

Claim 1 (Currently amended): A method of inhibiting endothelial cell growth in a subject in need of inhibiting endothelial cell growth, comprising:

contacting an endothelial cell in the subject with a polypeptide comprising an amino acid sequence at least ~~90%~~ 95% homologous to an amino acid sequence as set forth in SEQ ID NO: 2, or a therapeutically effective fragment thereof, wherein the polypeptide, or therapeutically effective fragment thereof, inhibits endothelial cell growth in the subject.

~~thereby inhibiting endothelial cell growth.~~

10-115-04, 76
Claim 2 (~~Withdrawn~~): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.

Claim 3 (~~Withdrawn~~): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 8.

Claim 4 (~~Withdrawn~~): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 5.

Claim 5 (Currently amended): A method of inhibiting angiogenesis in a subject in need of anti-angiogenic therapy, comprising:

administering to the subject a composition comprising a polypeptide comprising an amino acid sequence at least ~~90%~~ 95% homologous to an amino acid sequence as set forth in SEQ ID NO: 2, or a therapeutically effective fragment thereof, wherein the polypeptide, or therapeutically effective fragment thereof, inhibits angiogenesis in the subject.

~~thereby inhibiting angiogenesis in the subject.~~

Claim 6 (Previously presented): The method of claim 5, wherein the composition further comprises a pharmaceutically acceptable carrier.

my 10-15-04
Claim 7 (~~Withdrawn~~): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.

Claim 8 (~~Withdrawn~~): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 8.

Claims 9-12 (Canceled).

9
Claim ~~13~~ (Previously presented): The method of claim 5, further comprising administering an anti-angiogenic agent comprising platelet-factor-4, IP-10 (interferon (IFN)- γ inducible protein-10), MIG (Monokine induced by IFN- γ), INF- γ , IFN- α , angiostatin, endostatin, fumagillin, AGM-1470, thrombospondin, a fragment of prolactin, antibody against the integrin $\alpha_v\beta_3$, IL-12, cleaved conformation of the serpin antithrombin, thalidomide, or a mixture thereof.

10
Claim ~~14~~ (Previously presented): The method of claim 5, further comprising administering a chemotherapeutic agent.

11
Claim ~~15~~ (Previously presented): The method of claim 5, further comprising administering a hormone.

12
Claim ~~16~~ (Previously presented): The method of claim 5, further comprising administering an anti-inflammatory agent.

13
Claim ~~17~~ (Previously presented): The method of claim 5, further comprising administering an anti-viral agent.

Claim 18-19 (Canceled).

¹⁴
Claim ~~20~~ (Previously presented): The method of claim 5, wherein the subject has periodontal disease.

¹⁵
Claim ~~21~~ (Previously presented): The method of claim ~~20~~¹⁴, further comprising administering an antibiotic.

¹⁶
Claim ~~22~~ (Previously presented): The method of claim 5, wherein the subject has a radiation induced injury.

¹⁷
Claim ~~23~~ (Previously presented): The method of claim 5, wherein the subject has a chemotherapy induced injury.

¹⁸
Claim ~~24~~ (Previously presented): The method of claim 5, wherein the composition inhibits angiogenesis, wherein angiogenesis is stimulated in the subject by an angiogenesis inducer comprising basic fibroblast growth factor, acidic fibroblast growth factor, Vascular Endothelial Growth Factor (VEGF), hepatocyte growth factor, Interleukin (IL)-15, IL-8, platelet-derived endothelial cell growth factor (PDEC GF), Transforming Growth Factor (TGF)- β , Tumor necrosis Factor (TNF) α , angiogenin, cripto, or a mixture thereof.

¹⁹
Claim ~~25~~ (Original): The method of claim 5, wherein the subject is immunocompromized due to T-lymphocyte deficiency.

Claims 26-56 (Canceled).

²⁰
Claim ~~57~~ (Previously presented): The method of claim 1, wherein the therapeutically effective fragment of calcitriol consists essentially of:

- See
Examiner's
Amendment
10-15-04
y
- (a) an amino acid sequence as set forth in SEQ ID NO: 5;
 - (b) an amino acid sequence as set forth in SEQ ID NO: 6;
 - (c) an amino acid sequence as set forth in SEQ ID NO: 8;

- (d) an amino acid sequence as set forth in SEQ ID NO: 9; or
- (e) an amino acid sequence as set forth in SEQ ID NO: 4.

Claims 58-59 (Canceled).

²¹
Claim ~~60~~ (Previously presented): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 4.

²²
Claim ~~61~~ (Withdrawn): The method of claim 1, wherein the therapeutically effective fragment comprises SEQ ID NO: 9.

Claim 62 (Canceled).

²³
Claim ~~63~~ (Previously presented): The method of claim ~~62~~¹, wherein the polypeptide comprises an amino acid sequence at least 98% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

See Examiner's
Amendment
10-15-04
7

²⁴
Claim ~~64~~ (Previously presented): The method of claim 63, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

²⁵
Claim ~~65~~ (Withdrawn): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 5.

²⁶
Claim ~~66~~ (Previously presented): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 4.

²⁷
Claim ~~67~~ (Withdrawn): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 9.

Claim 68 (Canceled).

²⁸
Claim ~~69~~ (Previously presented): The method of claim ⁵~~68~~, wherein the polypeptide comprises an amino acid sequence at least 98% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

see
Examiner's
Amendment
10-15-04
y

²⁹
Claim ~~70~~ (Previously presented): The method of claim 69, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

Claims 71-76 (Canceled).

³⁰
Claim ~~77~~ (Previously presented): The method of claim 5, wherein the subject has Kaposi sarcoma.

³¹
Claim ~~78~~ (Previously presented): The method of claim 1, wherein the endothelial cell is *in vitro*.

³²
Claim ~~79~~ (Previously presented): The method of claim 1, wherein the endothelial cell is *in vivo*.

³³
Claim ~~80~~ (Previously presented): The method of claim 1, wherein the endothelial cell is in a tumor in a subject.

³⁴
Claim ~~81~~ (Previously presented): The method of claim 5, wherein the subject has a tumor.